vs
CoastalSouth Bancshares, Inc.（COSO）与X4 Pharmaceuticals, Inc（XFOR）财务数据对比。点击上方公司名可切换其他公司
X4 Pharmaceuticals, Inc的季度营收约是CoastalSouth Bancshares, Inc.的1.4倍（$28.8M vs $21.3M），CoastalSouth Bancshares, Inc.净利率更高（31.7% vs 1.0%，领先30.7%）
CoastalSouth Bancshares, Inc.是一家美国区域性银行控股企业，主要通过旗下附属银行开展业务，为美国墨西哥湾沿岸地区的零售客户与中小企业提供存款、消费贷款、商业融资、抵押贷款、财富管理等多元金融服务。
X4制药是一家临床阶段生物技术公司，专注于开发针对存在高度未满足医疗需求的罕见免疫疾病和肿瘤适应症的新型靶向疗法，主要运营市场覆盖美国与欧洲，核心管线包括WHIM综合征候选药物及多款免疫疾病、肿瘤领域的临床和临床前资产。
COSO vs XFOR — 直观对比
营收规模更大
XFOR
是对方的1.4倍
$21.3M
净利率更高
COSO
高出30.7%
1.0%
损益表 — Q3 FY2025 vs Q1 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.3M | $28.8M |
| 净利润 | $6.7M | $282.0K |
| 毛利率 | — | 83.6% |
| 营业利润率 | 41.2% | -32.8% |
| 净利率 | 31.7% | 1.0% |
| 营收同比 | — | — |
| 净利润同比 | — | 100.5% |
| 每股收益（稀释后） | $0.54 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COSOXFOR
| Q3 25 | $21.3M | — | ||
| Q2 25 | $19.9M | — | ||
| Q1 25 | — | $28.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 |
净利润COSOXFOR
| Q3 25 | $6.7M | — | ||
| Q2 25 | $6.0M | — | ||
| Q1 25 | — | $282.0K | ||
| Q1 24 | — | $-51.8M | ||
| Q3 23 | — | $-2.3M | ||
| Q2 23 | — | $-55.7M |
毛利率COSOXFOR
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.6% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
营业利润率COSOXFOR
| Q3 25 | 41.2% | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | — | -32.8% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
净利率COSOXFOR
| Q3 25 | 31.7% | — | ||
| Q2 25 | 30.0% | — | ||
| Q1 25 | — | 1.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
每股收益（稀释后）COSOXFOR
| Q3 25 | $0.54 | — | ||
| Q2 25 | $0.57 | — | ||
| Q1 25 | — | $0.04 | ||
| Q1 24 | — | $-7.77 | ||
| Q3 23 | — | $-0.01 | ||
| Q2 23 | — | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $40.3M |
| 总债务越低越好 | — | $75.0M |
| 股东权益账面价值 | $250.4M | $22.9M |
| 总资产 | $2.3B | $130.0M |
| 负债/权益比越低杠杆越低 | — | 3.27× |
8季度趋势，按日历期对齐
现金及短期投资COSOXFOR
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $40.3M | ||
| Q1 24 | — | $60.5M | ||
| Q3 23 | — | $131.6M | ||
| Q2 23 | — | $136.4M |
总债务COSOXFOR
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $75.0M | ||
| Q1 24 | — | $55.0M | ||
| Q3 23 | — | $55.0M | ||
| Q2 23 | — | $32.5M |
股东权益COSOXFOR
| Q3 25 | $250.4M | — | ||
| Q2 25 | $209.4M | — | ||
| Q1 25 | — | $22.9M | ||
| Q1 24 | — | $1.0M | ||
| Q3 23 | — | $67.6M | ||
| Q2 23 | — | $67.5M |
总资产COSOXFOR
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | — | $130.0M | ||
| Q1 24 | — | $112.2M | ||
| Q3 23 | — | $173.3M | ||
| Q2 23 | — | $173.4M |
负债/权益比COSOXFOR
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.27× | ||
| Q1 24 | — | 53.09× | ||
| Q3 23 | — | 0.81× | ||
| Q2 23 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $-12.4M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | — |
| 自由现金流率自由现金流/营收 | -27.7% | — |
| 资本支出强度资本支出/营收 | 1.9% | 0.0% |
| 现金转化率经营现金流/净利润 | -0.82× | -43.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流COSOXFOR
| Q3 25 | $-5.5M | — | ||
| Q2 25 | $-16.8M | — | ||
| Q1 25 | — | $-12.4M | ||
| Q1 24 | — | $-33.6M | ||
| Q3 23 | — | $-68.8M | ||
| Q2 23 | — | $-47.9M |
自由现金流COSOXFOR
| Q3 25 | $-5.9M | — | ||
| Q2 25 | $-17.9M | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | $-33.7M | ||
| Q3 23 | — | $-68.8M | ||
| Q2 23 | — | $-47.9M |
自由现金流率COSOXFOR
| Q3 25 | -27.7% | — | ||
| Q2 25 | -90.3% | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
资本支出强度COSOXFOR
| Q3 25 | 1.9% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
现金转化率COSOXFOR
| Q3 25 | -0.82× | — | ||
| Q2 25 | -2.82× | — | ||
| Q1 25 | — | -43.86× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
